CDTX Cidara Therapeutics Inc.

-0.05  -1%
Previous Close 6.95
Open 6.95
Price To book 1.90
Market Cap 116355356
Shares 16,863,095
Volume 21,695
Short Ratio 5.17
Av. Daily Volume 95,091

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated June 2016. Data due 4Q 2017.
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)

Latest News

  1. Cidara Therapeutics to Present at Two Upcoming Conferences
  2. Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 World Antimicrobial Resistance Congress
  3. T2 Biosystems and Cidara Therapeutics Announce Partnership for Commercial Placement of T2Dx Instruments to Support CD101 Drug Trials
  4. Cidara Therapeutics reports 2Q loss
  5. Cidara Therapeutics Announces Publication of Results from In Vivo Study Investigating Novel Antifungal CD101 in Intra-Abdominal Candidiasis (IAC)
  6. Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit
  7. Antimicrobial Working Group Members to Participate in 2017 BIO International Convention Panel
  8. Cidara Therapeutics to Participate in the 2017 BIO International Convention
  9. Cidara Therapeutics Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association
  10. Is a Surprise Coming for Cidara Therapeutics (CDTX) This Earnings Season?
  11. Cidara Therapeutics Announces Promotion of Taylor Sandison, M.D., M.P.H., to Chief Medical Officer
  12. Cidara Therapeutics to Present Data on Novel Antifungal CD101 and Cloudbreak Antibacterial Immunotherapy at ECCMID and SID Annual Meetings
  13. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  14. 3 of the Best & Worst Performing Drug Stocks of Q1
  15. Cidara Therapeutics Awarded $6.9 Million Grant from CARB-X to Advance Development of its First CloudbreakTM Antibiotic Immunotherapy